Shorts

0:51
James R. Porter, MD, on the telementoring capabilities of the Hugo RAS
7 months ago
by
James R. Porter, MD

1:12
Pearls & Perspectives: Normalizing sexual wellness conversations
7 months ago
by
Amy M. Pearlman, MD

1:13
Jennifer Miles-Thomas, MD, discusses areas of opportunity for urology APPs
7 months ago
by
Jennifer Miles-Thomas, MD, URPS, MBA

0:59
The Expert APProach: Preparing the Next Generation of APPs
7 months ago
by
Joy Maulik, CRNP(+1 more)

1:03
Akanksha Mehta, MD, on counseling men on vasectomy safety
7 months ago
by
Akanksha Mehta, MD, MS(+1 more)

1:10
Jonathan Anker, MD, on bladder-sparing approach in patients with MIBC
7 months ago
by
Jonathan F. Anker, MD, PhD

1:15
Daniel J. George, MD, on PTEN loss and prostate cancer prognosis
7 months ago
by
Daniel J. George, MD

1:02
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women
7 months ago
by
Alexandra Drakaki, MD, PhD

1:02
Pearls & Perspectives: What is “normal” urination frequency?
7 months ago
by
Amy M. Pearlman, MD

1:03
Giulia Almiron da R. Soares on social media and urology recruitment
7 months ago
by
Giulia Almiron da R. Soares

0:23
Jared S. Winoker, MD, on research comparing CVAC 2.0 vs FANS
7 months ago
by
Jared S. Winoker, MD

1:06
James R. Porter, MD, discusses haptics and the Hugo RAS system
8 months ago
by
James R. Porter, MD

0:37
Matthias Saar, MD, outlines the rationale for the phase 2 INDUCTA trial in prostate cancer
8 months ago
by
Matthias Saar, MD

1:13
Pearls & Perspectives: The trouble with voiding diaries
8 months ago
by
Amy M. Pearlman, MD

0:29
Is PCNL dead? with Ben H. Chew, MD, MSc, FRCSC
8 months ago
by
Ben H. Chew, MD, MSc

1:12
Alicia Morgans, MD, discusses cancer control with enzalutamide, apalutamide
8 months ago
by
Alicia Morgans, MD, MPH

1:05
Bogdana Schmidt, MD, MPH, on who could benefit most from ICI plus BCG in high-risk NMIBC
8 months ago
by
Bogdana Schmidt, MD, MPH

1:19
Neha Vapiwala, MD, explores the biggest prostate cancer takeaways from ASCO GU 2026
8 months ago
by
Neha Vapiwala, MD, FASTRO

1:12
Christopher Pieczonka, MD, on what’s next for NAI plus BCG in BCG-naïve NMIBC
8 months ago
by
Christopher Pieczonka, MD

0:42
Sara Coca Membribes, MD, on what’s needed to refine the role of BCG-ICI combinations in NMIBC
8 months ago
by
Sara Coca Membribes, MD

0:45
Jean-Nicolas Cornu, MD, PhD, FEBU, on the patient population of VAPEUR-RCT in BPH
8 months ago
by
Jean-Nicolas Cornu, MD, PhD, FEBU

0:41
Antoni Vilaseca Cabo, MD, on the pharmacokinetics of erda-iDRS in NMIBC
8 months ago
by
Antoni Vilaseca Cabo, MD

0:48
Daniel J. George, MD, on the need for caregiver support in prostate cancer
8 months ago
by
Daniel J. George, MD

0:34
Brian F. Chapin, MD, on adding local therapy to systemic treatment in metastatic prostate cancer
8 months ago
by
Brian F. Chapin, MD

0:43
Declan Murphy, MB, BCH, on the implications of PRIMARY2 study for prostate cancer diagnosis
8 months ago
by
Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol

1:02
Andrea Necchi, MD, on the SURE-02 trial evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab
8 months ago
by
Andrea Necchi, MD

1:12
Sam S. Chang, MD, MBA, on the significance of KEYNOTE-B15 data
8 months ago
by
Sam S. Chang, MD, MBA

1:08
James R. Porter, MD, on the modular architecture of the Hugo RAS
8 months ago
by
James R. Porter, MD

0:49
Maha Hussain, MD, on the significance of BRCAAway data in mCRPC
8 months ago
by
Maha H. A. Hussain, MD, FASCO, FACP

1:12
The Expert APProach: The importance of physician-directed care
8 months ago
by
Joy Maulik, CRNP
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC
3
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5
